Brainsway Ltd
Officers & Directors
Hadar Levy, age 52, has served as Chief Executive Officer since February 13, 2023. He was Senior Vice President and General Manager North America from May 2020 and Chief Financial Officer from September 2014 to May 2020. He has been a director at ReWalk Robotics Ltd. since July 2022. Levy holds a BA in Economics and Accounting from Ruppin, an LLM from Bar Ilan University, and is a Certified Public Accountant.
Ido Marom, age 50, has been Chief Financial Officer since May 2023. His previous roles include CFO of Surgical Theater Inc. since 2019, Finance Director at Amdocs, CFO and COO of The Jewish Agency in North America, and VP of Finance at Ness Technologies. Marom holds a BA in Accounting and Finance from Haifa University and is a Certified Public Accountant.
Gilead Moiseyev, PhD, age 54, has been Chief Technology Officer since March 2024. He was COO at Magenta Medical and worked for 16 years at Medinol. Moiseyev holds a B.Sc., M.Sc., and Ph.D. in Computational Mechanics from the Technion, Israel.
Yiftach Roth, PhD, age 56, has been Chief Scientist since 2010 and is a scientific founder and key inventor of Deep TMS technology. He worked at the Advanced Technology Center of Chaim Sheba Medical Center from 2003 to 2006. Roth holds B.Sc. and M.Sc. degrees in Physics and a Ph.D. in Medical Physics from Tel Aviv University.
Colleen Hanlon, PhD, age 46, has been Vice President of Medical Affairs since November 2022. She was a faculty member at the Medical University of South Carolina and a tenured professor at Wake Forest School of Medicine. Hanlon holds a B.S. from the University of Florida and a Ph.D. in Neurobiology from Duke University.
Brainsway Ltd currently has 129 employees.
News about Brainsway Ltd Key Personnel |
BrainsWay Pioneers New Frontiers in Mental Health Therapy as Israel’s Defense Ministry Endorses TMS for PTSDnn
In a significant advancement for mental health treatment in Israel, BrainsWay Ltd. a prominent player in the field of non-invasive neurostimulation, has received approval from the Ministry of Defense s Rehabilitation Department for the reimbursement of its Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for patients diagnosed with post-traumatic stress disorder (PTSD). This milestone, announced on September 10, 2024, marks a pivotal moment for mental health care within the Israeli public hospital system, where the demand for innovative treatment options is surging.
|
BrainsWay, a leading provider of advanced neurostimulation treatments, recently appointed Dr. Richard A. Bermudes as its Chief Medical Officer. With decades of experience in the field of Transcranial Magnetic Stimulation (TMS), Dr. Bermudes is widely regarded as one of the preeminent clinicians in the United States.
Transcranial Magnetic Stimulation (TMS) is a non-invasive procedure that uses magnetic fields to stimulate specific areas of the brain. It has emerged as a promising therapy for a range of psychiatric disorders, including depression, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD). As the demand for TMS treatments continues to grow, BrainsWay stands at the foref...
|
|
|
